
The final analysis of IMvigor130, a phase 3 study, reveals that first-line atezolizumab plus platinum-based chemotherapy (group A) demonstrated significant progression-free survival benefit compared to placebo plus chemotherapy (group C) in urothelial cancer. However, overall survival did not significantly differ between group A and C. Atezolizumab monotherapy (group B) also showed no significant overall survival improvement compared to group C. Safety analysis indicated an acceptable profile for atezolizumab monotherapy. The study enrolled 1213 patients and concluded that atezolizumab monotherapy did not surpass platinum-based chemotherapy in overall survival.
Like
Save
Share